Inovio Pharmaceuticals Reports Results for Quarter Ended June 30, 2026

What Happened
On August 12, 2026, Inovio Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2026 by issuing a press release and filing an 8-K (Item 2.02). The press release is furnished as Exhibit 99.1 to the 8-K and is incorporated by reference. The filing also includes the interactive XBRL cover page (Exhibit 104).

Key Details

• Filing date: August 12, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Reporting period: quarter ended June 30, 2026.
• Exhibit 99.1: press release announcing the quarterly financial results (furnished with the 8-K).
• Exhibit 104: Cover Page Interactive Data File provided in inline XBRL format.

Why It Matters
This 8-K notifies investors that Inovio has published its quarterly earnings and related financial information; investors should review the attached press release for specific figures on revenue, earnings, cash position, and any operational updates. Because Item 2.02 concerns results of operations and financial condition, the press release may affect perceptions of the company’s recent performance and near-term outlook. For full detail, read Exhibit 99.1 and watch for follow-up filings (e.g., Form 10-Q) that will contain the complete financial statements and management discussion.